INmune  slides again as Scotiabank, RJ cut ratings after Alzheimer’s drug miss

Published 01/07/2025, 18:08
© Reuters.

Investing.com -- INmune Bio (NASDAQ:INMB) shares fell another 6% to about $2.17 on Tuesday after brokerages downgraded the stock, saying failure of the company’s experimental Alzheimer’s drug XPro in a mid‑stage trial sharply weakens its investment case.

Scotiabank (TSX:BNS) cut its rating to Sector Underperform and slashed its price target to 60 cents saying the 203‑patient study’s inability to show cognitive benefit and calling a partner search for further development “quite challenging.”

Raymond James moved to Market perform from Outperform, saying XPro showed only a small, non‑statistically significant effect in a subgroup of patients with higher levels of brain inflammation, leaving “greater risk to this key programme” as it moves toward larger, longer trials.

The downgrades come on the heels of a 57% plunge on June 30, when INmune disclosed the data alongside a $19 million share sale that bolstered cash to roughly $29 million but diluted existing investors.

XPro targets soluble tumour‑necrosis factor, an inflammatory protein researchers believe may contribute to Alzheimer’s disease.

The study missed its primary endpoint after six months, and analysts said it may need to run longer to detect a meaningful effect. Both analysts questioned whether the small biotechnology firm has the resources to fund a pivotal Phase 3 trial without a larger partner.

Beyond XPro, Scotiabank expressed doubt about INmune’s chances of winning U.S. approval for CORDStrom in a rare skin disorder and said early cancer therapy INKmune lacks compelling data.

Raymond James said limited resources could slow those projects as well.

The latest drop leaves INmune down about 80% since Friday’s close, valuing the company at roughly $55 million, a fraction of the $250 million market capitalisation it commanded before the trial read‑out.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.